- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Zydus Lifesciences reports bigger-than-expected rise in Q3 profit
Bengaluru: Indian generic drugmaker Zydus Lifesciences reported a bigger-than-expected rise in third-quarter profit, driven by strong sales in its domestic and overseas markets.
Consolidated net profit for the company rose 27% to 7.90 billion rupees (about $95 million) for the three months ended Dec. 31, beating analysts' average estimate of 6.83 billion rupees, as per LSEG data.
Separately, Zydus Lifesciences approved the buyback of shares worth six billion rupees via tender offer route at a price of 1,005 rupees, a 25% premium to its closing price on Thursday.
Total revenue from operations rose 6% to 45.05 billion rupees, led by a 16% rise in the drugmaker's India formulations business and a 30% climb in its European and emerging markets business, which includes Mexico and African markets.
However, its U.S. formulations business fell 4.3% from last year.
India's generic drugmakers, which draw a significant share of revenue from the crucial U.S. market, are recovering from the effects of eroding prices in the largest drug market in the world.
Zydus Lifesciences competes with Cipla and Dr Reddy's for selling the generic version of Bristol-Myers Squibb's popular cancer drug Revlimid in the United States.
India and the U.S. make up almost 85% of Zydus Life's total revenue.
Cipla, Dr Reddy's, and Sun Pharma also beat their third-quarter profit estimates on strong domestic and U.S. sales.
On Thursday, its unit Zydus Wellness reported a slump in December-quarter profit on higher tax expenses.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story